rmdopen.bmj3d
Predictors of remission in patients with non-radiographic axial spondyloarthritis receiving open-label adalimumab in the ABILITY-3 study
Background This analysis assessed baseline predictors of remission in patients with non-radiographic axial spondyloarthritis (nr-axSpA) who received open-label adalimumab therapy. Methods ABILITY-3 ...
rmdopen.bmj3d
Efficacy and safety of pharmacological treatments in inclusion body myositis: a systematic review
Objective To identify the best evidence on the efficacy of treatment interventions for inclusion body myositis (IBM) and to describe their safety. Methods Systematic review of randomised controlled ...
rmdopen.bmj10d
Assessing the sensitivity to change of the OMERACT ultrasound structural gout lesions during urate-lowering therapy
Objectives To evaluate the sensitivity to change of ultrasound structural gout lesions, as defined by the Outcome Measures in Rheumatology (OMERACT) ultrasound group, in patients with gout during ...
rmdopen.bmj3d
Artificial intelligence in rheumatology research: what is it good for?
Artificial intelligence (AI) is transforming rheumatology research, with a myriad of studies aiming to improve diagnosis, prognosis and treatment prediction, while also showing potential capability to ...
rmdopen.bmj6d
Risk for infections with glucocorticoids and DMARDs in patients with rheumatoid arthritis
Immunomodulatory therapy for rheumatoid arthritis (RA) carries risk for infectious complications. Understanding the risks of different therapeutic options is essential for making treatment decisions ...
rmdopen.bmj3d
Diagnostic spectrum and 2-year outcome in a cohort of patients with very early arthritis
Objectives To describe the diagnostic spectrum, arthritis persistency and clinical outcomes after 2 years in patients with inflammatory arthritis (IA) of less than 16 weeks’ duration. Methods Data ...
rmdopen.bmj10d
Anti-RNP positivity in primary Sjögren’s syndrome is associated with a more active disease and a more frequent muscular and pulmonary involvement
1 Department of Rheumatology, AP-HP, Paris-Sud University Hospitals, Le Kremlin-Bicêtre Hospital, Le Kremlin-Bicêtre, France 2 INSERM U1184, Center for Immunology of Viral Infections and Autoimmune ...
rmdopen.bmj16d
EULAR Sjögren's syndrome disease activity index (ESSDAI): a user guide
The EULAR Sjögren's syndrome (SS) disease activity index (ESSDAI) is a systemic disease activity index that was designed to measure disease activity in patients with primary SS. With the growing use ...
rmdopen.bmj27d
Triple jump for the optimal management of psoriatic arthritis: diet, sleep and exercise – a review
Psoriatic arthritis (PsA) is a complex, multiform and chronic inflammatory disease characterised by the association of arthritis and psoriasis combined with other related conditions and comorbidities.
rmdopen.bmj23d
Efficacy of BAFF inhibition and B-cell depletion in non-obese diabetic mice as a spontaneous model for Sjögren’s disease
Introduction The therapeutic interest of targeting B-cell activating factor (BAFF) in Sjögren’s disease (SjD) can be suspected from the results of two phase II clinical trials but has not been ...
rmdopen.bmj26d
Feasibility of cardiovascular disease risk assessments in rheumatology outpatient clinics: experiences from the nationwide NOCAR project
Objective The European League Against Rheumatism recommends implementing cardiovascular disease (CVD) risk assessments for patients with inflammatory joint diseases (IJDs) into clinical practice. Our ...
rmdopen.bmj24d
Mixed connective tissue disease: state of the art on clinical practice guidelines
Mixed connective tissue disease (MCTD) is a complex overlap disease with features of different autoimmune connective tissue diseases (CTDs) namely systemic sclerosis, poly/dermatomyositis and systemic ...